About Concentric Analgesic
Concentric Analgesic is a company based in San Francisco (United States) founded in 2014 by John Donovan and Craig Husfeld. Concentric Analgesic has raised $85.46 million across 4 funding rounds from investors including TD Securities, Oracle Investment Management and Venrock Capital Partners. Concentric Analgesic offers products and services including TRPV1 Agonist Prodrugs. Concentric Analgesic operates in a competitive market with competitors including Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter San Francisco, United States
- Founders John Donovan, Craig Husfeld
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Concentric Analgesics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$85.46 M (USD)
in 4 rounds
-
Latest Funding Round
$77.1 M (USD), Series B
May 21, 2019
-
Investors
TD Securities
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Concentric Analgesic
Concentric Analgesic offers a comprehensive portfolio of products and services, including TRPV1 Agonist Prodrugs.
Provides long-lasting non-opioid pain relief via single local injection.
People of Concentric Analgesic
Unlock access to complete
Unlock access to complete
Funding Insights of Concentric Analgesic
Concentric Analgesic has successfully raised a total of $85.46M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $77.1 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Concentric Analgesic
Concentric Analgesic has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include TD Securities, Oracle Investment Management and Venrock Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC & PE firm focused on healthcare sector
|
Locked | Locked | Locked | |
|
US private equity investments are managed by Kern Whelan Capital.
|
Locked | Locked | Locked | |
|
Research-driven investment firm focused on global health care and bioscience sectors.
|
Locked | Locked | Locked |
Investor details for Concentric Analgesic
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Concentric Analgesic
Investment portfolio details for Concentric Analgesic
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Concentric Analgesic
Detailed financials for Concentric Analgesic
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Concentric Analgesic Comparisons
Peer comparison for Concentric Analgesic
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Concentric Analgesic
Concentric Analgesic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Concentric Analgesic
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Concentric Analgesic
Complete news archive for Concentric Analgesic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Concentric Analgesic
Concentric Analgesic was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Concentric Analgesic is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Frank J Bellizzi is the current CEO of Concentric Analgesic.
Concentric Analgesic is a funded company, having raised a total of $85.46M across 4 funding rounds to date.
Concentric Analgesic was founded in 2014 in San Francisco, United States, and operates in the biotechnology sector focused on analgesics. A platform for the discovery and development of pro-drugs is maintained, emphasizing non-opioid options that aim to reduce opioid consumption. The lead candidate, CA-008, a water-soluble prodrug converting to capsaicin as a TRPV1 agonist, is currently in phase II clinical trials.
Concentric Analgesic's top competitors include Sutro Biopharma, Flexion Therapeutics and Avidity Biosciences.
Concentric Analgesic offers TRPV1 Agonist Prodrugs.
Concentric Analgesic has 4 investors. Key investors include TD Securities, Oracle Investment Management, Venrock Capital Partners, and Kern Whelan Capital.